Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. (Q35827517)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2006

Language	Label	Description	Also known as
English	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.	scientific article published in April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

based on heuristic

inferred from title

Ingolf Cascorbi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Annika Bernsdorf

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thomas Giessmann

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christiane Modess

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Danilo Wegner

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Stefanie Igelbrink

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ute Hecker

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sierk Haenisch

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Bernd Terhaag

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Werner Siegmund

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

0 references

publication date

1 April 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

61

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

440-450

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

Stereoselective disposition of talinolol in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

Drug interactions of the statins and consequences for drug selection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

HMG-CoA reductase inhibitors and P-glycoprotein modulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

Clinical pharmacokinetics and practical applications of simvastatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

The biliary elimination of the selective beta-receptor blocking drug talinolol in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885036

27 July 2018

Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

P-glycoprotein and surfactants: effect on intestinal talinolol absorption

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Simvastatin and lovastatin, but not pravastatin, interact with MDR1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Identification of functionally variant MDR1 alleles among European Americans and African Americans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

Grapefruit juice ingestion significantly reduces talinolol bioavailability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02599.X

21 January 2018

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/16542205

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2006.02599.X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16542205%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35827517&oldid=1523177147"